Research Topics
Genomes and GenesSpecies | Diane JelinekSummaryAffiliation: Mayo Clinic Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphomaJames R Cerhan
Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Blood 110:4455-63. 2007....
Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expressionD F Jelinek
Department of Immunology, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
J Clin Invest 99:447-56. 1997..Identification of these mechanisms may allow development of agents that are more universally effective than IFN-alpha...
Identification of a global gene expression signature of B-chronic lymphocytic leukemiaDiane F Jelinek
Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic, Rochester, MN 55905, USA
Mol Cancer Res 1:346-61. 2003..Finally, we identified a group of 31 genes that distinguish between low (Rai stage 0) and high (Rai stage 4) risk patients, suggesting that there may also be a gene expression signature that associates with disease progression...
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survivalAnne J Novak
Department of Immunology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905
Blood 103:689-94. 2004..Expression of BCMA, TACI, and BAFF-R by MM taken together with the ability of BLyS to support MM cell growth and survival has exciting implications because they may be potential therapeutic targets...
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemiaD F Jelinek
Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
Br J Haematol 115:854-61. 2001..These data strongly encourage the study of these biological markers as they relate to disease heterogeneity in B-CLL...
Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptorsDiane F Jelinek
Department of Immunology, Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Curr Dir Autoimmun 8:266-88. 2005..In this article, we will review the spectrum of human B lineage malignancies and discuss current evidence supporting a role for BLyS and APRIL in fueling the growth and survival of specific B cell malignancies...
A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growthD F Jelinek
Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
J Immunol 159:487-96. 1997..In summary, these studies suggest that IGFs may play an important role in multiple myeloma by virtue of their ability to directly stimulate tumor cell growth as well as modulate the magnitude of IL-6-driven growth...
Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approachJ D French
Dept of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 16:1189-96. 2002..Importantly, this interaction has not been noted in studies utilizing the same gp130 chimeric receptor system in non-MM cells...
Dissection of the signalling requirements of interleukin-6-stimulated myeloma cell growthJ D French
Department of Immunology, Mayo Graduate and Medical School, Mayo Clinic, Rochester, Minnesota, USA
Acta Oncol 39:777-81. 2000..This combined approach has the potential to assess the relative importance of several signalling events in myeloma cell growth control and identify IL-6 responsive genes in this malignancy...
Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurinesCarlton W Thomas
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st St. SW, Rochester, MN 55905, USA
J Pharmacol Exp Ther 312:537-45. 2005..These results therefore provide a previously unrecognized molecular mechanism for the immunosuppressive properties of thiopurine antimetabolite drugs...
Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemiaTait Shanafelt
Department of Medicine, Mayo Clinic, Rochester, MN 55902, USA
Leuk Lymphoma 51:2222-9. 2010..No complete or partial remissions were observed. Individually and collectively, these studies indicate that single-agent anti-VEGF therapy has minimal clinical activity for patients with relapsed/refractory CLL...
Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphomaS M Ansell
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Leukemia 18:616-23. 2004..We conclude that inhibition of survivin expression is an attractive therapeutic strategy in aggressive non-Hodgkin's lymphomas, and that combining survivin ASO with rituximab may enhance the efficacy of this approach...
B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic moleculesN E Kay
Department of Medicine, Division of Hematology, Mayo Graduate and Medical Schools, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leukemia 16:911-9. 2002....
VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistanceY K Lee
Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Leukemia 19:513-23. 2005..Thus, a VEGF-VEGF receptor pathway in CLL B cells can be linked to activation of STAT proteins that are able to enhance their apoptotic resistance...
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort studyAngela Dispenzieri
Hematology, Mayo Clinic, Rochester, MN 55905, USA
Lancet 375:1721-8. 2010..The remaining 20% are characterised by absence of IgH expression; we aimed to assess prevalence of a corresponding precursor entity, light-chain MGUS...
Sharpening spots: correcting for bleedover in cDNA array imagesTerry Therneau
Department of Health Sciences Research, Mayo Foundation, Rochester, MN 55905, USA
Math Biosci 176:1-15. 2002..The sharpened images look like a set of donuts, which concurs with our knowledge of the spotting process. Oversharpened images are actually useful as well, in locating the centers of each spot...
Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cellsB K Arendt
Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic/Foundation, Rochester, MN 55905, USA
Leukemia 16:2142-7. 2002....
CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulationB T Pittner
Department of Immunology and Division of Hematology, Mayo Clinic College of Medicine, Mayo Graduate School, Rochester, MN 55905, USA
Leukemia 19:2264-72. 2005..Taken together, these data suggest that CD38 is a marker of a more recently activated CLL B cell. This in turn may explain the biological and clinical differences between CD38-positive type B-CLL and CD38-negative type B-CLL...
ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotypeJ C Nolz
Department of Immunology, Mayo Clinic College of Medicine, Mayo Graduate School, Rochester, MN 55905, USA
Leukemia 19:1018-24. 2005..These results provide new insight into normal human B-cell biology as well as provide clues about the transformed cell in B-CLL...
Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcomeS M Ansell
Division of Hematology and Internal Medicine, Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 19:720-6. 2001..This finding provides a strong rationale for the investigation of cellular immunotherapy in B-cell NHL...
The effectiveness of double-stranded short inhibitory RNAs (siRNAs) may depend on the method of transfectionD K Walters
Department of Immunology, Tumor Biology Program, Mayo Graduate and Medical Schools, Mayo Clinic/Foundation, Rochester, MN 55905, USA
Antisense Nucleic Acid Drug Dev 12:411-8. 2002..Thus, our studies illustrate the striking dependence of dsRNA-mediated gene silencing in some cells on the methods of dsRNA transfection...
Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemiaRebekah L Browning
Ohio State University, Columbus, OH, United States
Leuk Res 31:1737-40. 2007..199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted...
Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic testGrzegorz S Nowakowski
Division of Hematology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 82:449-53. 2007..001). The percentage of smudge cells as a continuous variable correlated with overall survival (P=.04). The estimation of smudge cells on a blood smear could be a universally available prognostic test in early-stage CLL...
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemiaTait D Shanafelt
Mayo Clinic College of Medicine, Department of Internal Medicine, Division of Hematology, Rochester, MN 55905, USA
J Clin Oncol 24:4634-41. 2006..These findings have important implications for both clinical management and trials of early treatment for patients with high-risk, early-stage CLL...
Clinical course and prognosis of smoldering (asymptomatic) multiple myelomaRobert A Kyle
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
N Engl J Med 356:2582-90. 2007..Prognostic factors for the progression and outcome of this disease are unclear...
Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cellsJaime R Darce
Department of Immunology, Mayo Clinic College of Medicine, Mayo Graduate School, 200 First Street Southwest, Rochester, MN 55905, USA
J Immunol 178:5612-22. 2007..Taken together, these data define a complex role for BAFF in humoral immune responses and show for the first time that BAFF can also play an inhibitory role in B cell differentiation...
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaAngela Dispenzieri
Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
Blood 111:785-9. 2008..The serum immunoglobulin FLC ratio is an important additional determinant of clinical outcome in patients with SMM...
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximabClive S Zent
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
Cancer 113:2110-8. 2008..In this phase 2 study, the authors tested the safety and efficacy of early treatment for patients with high-risk CLL using alemtuzumab and rituximab...
Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2Bonnie K Arendt
Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
Blood 112:1931-41. 2008..Moreover, these cell lines will provide an invaluable tool to better understand AL, from the combined perspectives of amyloidogenic protein structure and amyloid formation, genetics, and cell biology...
Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expressionTait D Shanafelt
J Clin Oncol 26:e5-6. 2008
Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemiaShanique Palmer
Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Br J Haematol 141:607-14. 2008..These characteristics can be modified and continued evaluation of immunomodulatory drugs, vaccination strategies and cellular therapies to delay/prevent disease progression are warranted...
The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphomaClive S Zent
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 141:615-21. 2008..Revisions of the National Cancer Institute Working Group 96 criteria should consider the aetiology of cytopenia in staging CLL patients...
CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potentialTait D Shanafelt
Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Br J Haematol 140:537-46. 2008..Importantly, anti-CD49d antibodies are already approved for treatment of other human diseases. Clinical testing of anti-CD49d therapy in CLL appears warranted...
MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)?Tait D Shanafelt
Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States
Leuk Res 32:1458-61. 2008..In contrast, CD38 predicted TTT (p=0.02) regardless of the proposed new classification. Molecular characteristics of the leukemic clone are a better predictor of progression than an arbitrary ALC or B lymphocyte count threshold...
Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patientsRenee C Tschumper
Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
J Clin Invest 118:306-15. 2008..In addition, these data support the concept that antigen-driven selection of specific Ig receptors plays a role in the clinical course of B-CLL...
Regulated expression of BAFF-binding receptors during human B cell differentiationJaime R Darce
Department of Immunology, Mayo Clinic College of Medicine, Mayo Graduate School, Rochester MN 55905, USA
J Immunol 179:7276-86. 2007..Collectively, our data suggest that the BBR profile may serve as a footprint of the activation history and stage of differentiation of normal human B cells...
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaNeil E Kay
Mayo Clinic, Stabile 628, 200 First St SW, Rochester, MN 55905, and The Ohio State University, Columbus, USA
Blood 109:405-11. 2007....
A role for BLyS in the activation of innate immune cellsSook Kyung Chang
Department of Immunology, Guggenheim 4, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Blood 108:2687-94. 2006..Moreover, this study may explain more clearly why high BLyS production is often correlated with certain inflammatory autoimmune diseases and B-lymphocyte malignancies...
A role for Janus kinases in crosstalk between ErbB3 and the interferon-alpha signaling complex in myeloma cellsDenise K Walters
Department of Immunology, Tumor Biology Program, Mayo Graduate and Medical Schools, Mayo Clinic Foundation, Rochester, MN 55905, USA
Oncogene 23:1197-205. 2004..These findings validate our previous report of ErbB3 involvement in IFN-alpha-induced proliferation and further suggest that both Janus kinase members, Tyk2 and Jak1, play a role in the transactivation of ErbB3 in this model system...
IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cellsJun Won Lee
Department of Medicine, Hematology Oncology Division, University of Pittsburgh, and Department of Vetrerans Affairs Medical Center, PA 15213, USA
Blood 103:2308-15. 2004..These data suggest that increased IL-3 levels in the bone marrow microenvironment of MM patients with imbalanced AML-1A and AML-1B expression can increase bone destruction and tumor cell growth...
Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complexDenise K Walters
Department of Immunology, Tumor Biology Program, Mayo Graduate and Medical Schools, Mayo Clinic Foundation, Rochester, MN 55905, USA
Oncogene 22:3598-607. 2003..These results suggest that ErbB3 expression alone does not uniquely confer IFN-alpha growth responsiveness, but instead may amplify proliferation rates in MM cells that have acquired atypical expression of this receptor...
Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemiaGordon W Dewald
Division of Laboratory Genetics, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 121:287-95. 2003..Importantly, only CD38+ was significantly associated with high-risk FISH categories (+12, 11q- and 17p-) after adjustment for the effects of other variables...
Transactivation of gp130 in myeloma cellsJena D French
Department of Immunology, Mayo Graduate and Medical Schools, Mayo Clinic, Rochester, MN 55905, USA
J Immunol 170:3717-23. 2003..Finally, transactivation of gp130 may be a common theme in myeloma cells, perhaps providing a mechanism for enhanced or qualitatively distinct cellular responses to specific stimuli...
AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myelomaSun J Choi
Department of Medicine Hematology Oncology, University of Pittsburgh, PA, USA
Blood 101:3778-83. 2003..The data suggest that strategies that enhance AML-1B expression or decrease AML-1A in MM cells may be beneficial therapeutically...
Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survivalAnne J Novak
Departments of Immunology, Pediatric and Adolescent Medicine, and Internal Medicine, Mayo Graduate and Medical Schools, Mayo Clinic, Rochester, MN 55905, USA
Blood 100:2973-9. 2002..Because these molecules are key regulators of B-cell homeostasis and tumor progression, leukemic cell autocrine expression of BLyS and APRIL may be playing an important role in the pathogenesis of this disease...
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphomaStephen M Ansell
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Blood 99:67-74. 2002..These data suggest that IL-12 and rituximab is an active combination and further studies of this combination in B-cell non-Hodgkin lymphoma are warranted...
VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemiaYean K Lee
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Blood 104:788-94. 2004..Thus, these results suggest that VEGF signaling regulates survival signals in CLL cells and that interruption of this autocrine pathway results in caspase activation and subsequent leukemic cell death...
Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcomeAnne J Novak
Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Blood 104:2247-53. 2004..In summary, we found that BLyS and its receptors represent a potentially important therapeutic target in B-cell lymphoma...
Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemiaStephanie R Fink
Division of Laboratory Genetics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 29:253-62. 2005..Deletions in IGHv occurred in 25% of patients and correlated with IGHv gene expression. Probes for 6q23 detected more deletions in 6q than probes for 6q21...
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myelomaWee J Chng
Department of Hematology-Oncology, Mayo Clinic Scottsdale, 13208 E Shea Blvd, Suite 300, Scottsdale, AZ 85259, USA
Blood 108:2755-63. 2006..Thus, IL6 and its downstream signaling may be of biologic importance in WM. Further elucidation of the role of IL-6 in WM is warranted as this may offer a potential therapeutic avenue...
Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disordersAnne J Novak
Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 24:983-7. 2006..6-fold increase in activity (P = .004). CONCLUSION: Our data suggest serum BLyS levels are elevated in patients with familial B-CLL and that elevated BLyS levels correlate with the presence of a T at -871 in the BLyS promoter...
A-Miz-ing BCL6Xiaosheng Wu
Nat Immunol 6:964-6. 2005
Quantitative protein expression analysis of CLL B cells from mutated and unmutated IgV(H) subgroups using acid-cleavable isotope-coded affinity tag reagentsDavid R Barnidge
Mayo Proteomics Research Center, Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
J Proteome Res 4:1310-7. 2005..These results demonstrate that stable isotope labeling and mass spectrometry can complement 2D gel electrophoresis and gene microarray technologies for identifying putative and perhaps unique prognostic markers in CLL...
A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cellsNeil E Kay
Mayo Clinic, Stabile 628, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 29:1009-18. 2005..These studies suggest that the IL-4R, on B-CLL cells, can serve as a unique molecular target for directing cytotoxic agents in the therapy of B-CLL...
Protein expression profiling of CLL B cells using replicate off-line strong cation exchange chromatography and LC-MS/MSDavid R Barnidge
Mayo Proteomics Research Center, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA
J Chromatogr B Analyt Technol Biomed Life Sci 819:33-9. 2005..We show that despite the variance in SCX, capillary LC, and the data-dependent selection of precursor ions, an overlap of 64% between proteins identified in replicate runs was achieved for this system...
MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cellsYasuo Oba
Department of Medicine Hematology Oncology Division, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
Exp Hematol 33:272-8. 2005..Several chemokine receptors (CCR1, CCR5, and CCR9) mediate the effects of MIP-1alpha. In this study, we determined which of these mediates the effects of MIP-1alpha on human OCL formation and myeloma cells...
B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturationSook Kyung Chang
Department of Immunology, College of Medicine, Mayo Graduate School, Mayo Clinic, Rochester, MN 55905, USA
J Immunol 180:7394-403. 2008..Collectively, our data suggest that BLyS may modulate adaptive immune cells indirectly by inducing DC maturation...
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997Michael R Grever
Eastern Cooperative Oncology Group, Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
J Clin Oncol 25:799-804. 2007..1), and p53 mutations have been reported to predict the clinical course and overall survival of patients with chronic lymphocytic leukemia (CLL). In addition, ZAP-70 and Bcl-2 family proteins have been explored as predictors of outcome...
Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic featuresDeborah A Bowen
Mayo Clinic College of Medicine, Rochester, Minnesota 55902, USA
Leuk Lymphoma 48:2412-7. 2007..Three-year survival was 41% (95% CI: 26 - 66%). HDMP-rituximab is an active regimen in patients with relapsed, refractory, and cytogenetically high-risk CLL. Further evaluation of this regimen in controlled trials appears warranted...
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemiaKami Maddocks Christianson
Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Br J Haematol 139:398-404. 2007..Physicians should strictly adhere to established criteria to initiate treatment for CLL patients who are not participating in clinical trials...
Research Grants
- Role of the BCR in B Cell Chronic Lymphocytic LeukemiaDiane Jelinek; Fiscal Year: 2009..Through these studies, we aim to add novel insight into the etiology of this disease and are optimistic that this information can be used to devise timely novel therapeutic interventions. ..
- role of BLyS/April in Normal and Malignant Plasma CellsDiane Jelinek; Fiscal Year: 2007..abstract_text> ..
- MOLECULAR AND BIOLOGICAL FUNCTION OF CD40 IN MYELOMADiane Jelinek; Fiscal Year: 2002....
- Role of the BCR in B Cell Chronic Lymphocytic LeukemiaDiane F Jelinek; Fiscal Year: 2010..Through these studies, we aim to add novel insight into the etiology of this disease and are optimistic that this information can be used to devise timely novel therapeutic interventions. ..
